Condition: Non-hodgkin Lymphoma · Acute Lymphoblastic Leukaemia · Chronic Lymphocytic Leukemia · Sponsor: CytoCares Inc
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.
This description comes directly from the study's public registry record.
ZHEN JING, MM · 86-21-50582090 · zhen.jing@cytocares.com
Always discuss trial participation with your own doctor first.
| InstituteHBDH | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06037018